SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999; 340: 13301340.
  • 2
    Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. Mechanisms of disease: the biology of chronic myelogenous leukemia. N Engl J Med. 1999; 341: 164172.
  • 3
    Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the p210bcr/abl gene of the Philadelphia chromosome. Science. 1990; 247: 824830.
  • 4
    Druker BJ, Lydon NB. Lessons learned from the development of an ABL tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000; 105: 37.
  • 5
    Buchdunger E, Zimmerman J, Mett H, et al. Inhibition of the Abl protein tyrosine kinase in vitro an in vivo by a 2-phenilaminopyrimidine derivative. Cancer Res. 1996; 56: 100104.
  • 6
    Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561566.
  • 7
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 10311037.
  • 8
    Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645652.
  • 9
    O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 9941004.
  • 10
    Rosti G, Martinelli G, Bassi S, et al. Molecular response to imatinib in chronic phase chronic myeloid leukemia. Blood. 2004; 15: 22842290.
  • 11
    Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanism of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003; 4: 7585.
  • 12
    Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293: 876880.
  • 13
    Branford S, Rudzky Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003; 102: 276283.
  • 14
    Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia. 2004; 18: 401408.
  • 15
    Nieborowska-Storska M, Slupianek A, Skorski T. Progressive changes in the leukemogenic signaling in BCR/ABL transformed cells. Oncogene. 2000; 19: 41174124.
  • 16
    Hoover RR, Mahon FX, Melo JV, Dalay GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 2002; 100: 10681071.
  • 17
    Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell. 1990; 60: 509520.
  • 18
    Miller RW, Fraumeni JF, Manning MD. Association of Wilms' tumor with aniridia, hemihypertrophy and other congenital anomalies. N Engl J Med. 1964; 270: 922927.
  • 19
    Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia. 2002; 16: 21152121.
  • 20
    Elisseeva OA, Oka Y, Tsuboi A, et al. Humoral immune response against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood. 2002; 99: 32723279.
  • 21
    Cilloni D, Saglio G. Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy. Semin Hematol. 2003; 40: 3741.
  • 22
    Cilloni D, Messa F, Gottardi E, et al. Very significant correlation between WT1 expression level and the International Prognostic Scoring System score in patients with myelodysplastic syndromes. J Clin Oncol. 2003; 21: 19881995.
  • 23
    Kantarjian H, Sawyers C, Hochhaus A, et al. Hematological and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645652.
  • 24
    National Cancer Institute Cancer Therapy Evaluation Program. Common toxicity criteria. Version 2.0. Bethesda: National Cancer Institute, 1998.
  • 25
    Cilloni D, Carlo-Stella C, Falzetti F, et al. Limited engraftment capacity of bone marrow-derived mesenchymal cells following T cell depleted hematopoietic stem cell transplantation. Blood. 2000; 96: 36373643.
  • 26
    Carlo-Stella C, Regazzi E, Sammarelli G, et al. Effects of the tyrosine kinase inhibitor AG957 and an anti-fas receptor antibody on CD34+ chronic myelogenous leukemia progenitor cells. Blood. 1999; 93: 39733982.
  • 27
    Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C. K252a inhibits the oncogenic properties of Met, the HGf receptor. Oncogene. 2002; 21: 48854893.
  • 28
    van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999; 13: 19011928.
  • 29
    Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood. 1996; 87: 28782884.
  • 30
    Cross NC, Chase A, Seear RV, et al. The utility of in vitro testing for imatinib sensitivity in BCR-ABL negative myeloproliferative disorders [abstract]. Hematol J. 2003; 4: 129.